MENU

BIIB Stock Tickeron detected bullish Stock Pattern: Broadening Wedge Ascending BIIB on November 13, 2025, netting in a 7.34% gain over 1 week

A.I.dvisor
at Tickeron.com
Loading...
+7.34% Gain from a Successful pattern Broadening Wedge Ascending
BIIB - Biogen
Tickeron
Ticker: BIIB
Company: Biogen
Gain: +7.34%
Confirmed: 11/13/25
Succeeded: 11/24/25
Total length: 11 days

On November 13, 2025, A.I.dvisor detected a Broadening Wedge Ascending Pattern (Bullish) for Biogen (BIIB, $164.73). On November 13, 2025, A.I.dvisor confirmed the Bullish pattern, setting a target price of $181.60. 11 days later, on November 24, 2025, BIIB reached the target price resulting in a for traders who took a long position in the stock.

BIIB's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for BIIB turned positive on October 31, 2025. Looking at past instances where BIIB's MACD turned positive, the stock continued to rise in of 59 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in of 265 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 173 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 19 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BIIB broke above its upper Bollinger Band on November 25, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. BIIB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.456) is normal, around the industry mean (8.915). P/E Ratio (16.477) is within average values for comparable stocks, (23.825). BIIB's Projected Growth (PEG Ratio) (5.257) is slightly higher than the industry average of (2.041). BIIB's Dividend Yield (0.000) is considerably lower than the industry average of (0.026). P/S Ratio (2.631) is also within normal values, averaging (3.624).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.

View a ticker or compare two or three
BIIB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. BIIB showed earnings on October 30, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Biotechnology
Address
225 Binney Street
Phone
+1 617 679-2000
Employees
7570
Web
https://www.biogen.com